An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of Two Forms ofGSK1363089 in Subjects With Solid Tumors

Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of solid tumor malignancy.

- 18 years old with ECOG of 0-1.

- female subject who is not pregnant

- Male subjects must agree to use contraception methods

- Able to swallow and retain oral medication.

- The subject will refrain from the use of illicit drugs and adhere to other
protocol-stated restrictions while participating in the study.

- QTcB or QTcF < 470 msec.

- Bilirubin = 1.5mg/dl, AST, ALT, ALP <2X ULN in absence of malignant disease in the
liver or <5X ULN in case of liver involvement by the tumor.

- Serum Creatinine <1.5mg/dL

Exclusion Inclusion:

- The subject has received anticancer treatment.

- The subject has participated in a clinical trial and has received an investigational
product within 21 days.

- The subject has known brain metastases.

- The subject has uncontrolled intercurrent illness.

- History of sensitivity to any of the study medications, or components.

- The subject is known to be positive for the human immunodeficiency virus (HIV).

- Subjects who have had partial or complete gastrectomy.

- Pregnant females as determined by positive ß-hCG test at screening or prior to
dosing.

- Lactating females.

- Unwillingness or inability to follow the procedures outlined in the protocol.